Core Insights - The average stock price of A-shares is 13.99 yuan, with 155 stocks priced over 100 yuan, an increase of 4 from the previous trading day [1] - The Shanghai Composite Index closed at 4007.76 points, up 0.97%, while stocks over 100 yuan had an average increase of 2.34%, outperforming the index by 1.37 percentage points [1] - The top-performing stocks over 100 yuan include Cambrian Technology, Kweichow Moutai, and Yuanjie Technology, with closing prices of 1480.00 yuan, 1435.13 yuan, and 616.53 yuan respectively [1] Market Performance - The average increase of stocks priced over 100 yuan in the last month was 0.44%, while the Shanghai Composite Index rose by 3.22% [2] - Notable gainers in the past month include Yunhan Chip City, Xiangnan Chip Creation, and Ding Tai High-Tech, with increases of 82.01%, 76.54%, and 65.38% respectively [2] - Year-to-date, the average increase of stocks over 100 yuan is 109.55%, outperforming the Shanghai Composite Index's 89.98% [2] Industry Distribution - The majority of stocks over 100 yuan are concentrated in the electronics, computer, and machinery sectors, with 58 stocks from the electronics sector, accounting for 37.42% of the total [2] - The stock distribution by board shows that there are 31 stocks from the main board, 50 from the ChiNext, 4 from the Beijing Stock Exchange, and 70 from the Sci-Tech Innovation Board, with the latter making up 45.16% of the total [2] Institutional Ratings - Five stocks priced over 100 yuan received "buy" ratings from institutions, including Zhaoyi Innovation, Wancheng Group, and Tuojing Technology, with Tuojing Technology being newly covered by institutions [2] - Among the rated stocks, two have target prices indicating an upside potential exceeding 10%, with Jinbo Biological having the highest potential of 48.88% [3]

Group 1 - The medical beauty sector increased by 0.18% on November 6, with *ST Meigu leading the gains [1] - The Shanghai Composite Index closed at 4007.76, up 0.97%, while the Shenzhen Component Index closed at 13452.42, up 1.73% [1] - The trading volume and turnover for *ST Meigu were 137,900 hands and 53.13 million yuan, respectively, with a price increase of 3.95% [1] Group 2 - The medical beauty sector experienced a net outflow of 34.96 million yuan from main funds, while retail investors saw a net inflow of 36.62 million yuan [1] - Individual stock performances included *ST Meigu with a 3.95% increase, Aimeike with a 0.38% increase, Huaxi Biological with a 0.52% decrease, and Jinbo Biological with a 2.54% decrease [1] - The net fund flow for *ST Meigu was -3.52 million yuan, indicating a decrease of 6.63% [2]

Core Points - On November 6, the A-share market saw all three major indices rise, with the Shanghai Composite Index increasing by 0.97% to surpass 4000 points, the Shenzhen Component Index rising by 1.73%, and the ChiNext Index up by 1.84% [1] - The total trading volume in the Shanghai and Shenzhen markets was approximately 205.52 billion yuan, an increase of about 18.29 billion yuan compared to the previous trading day [1] - Out of 2880 stocks in the market, 2388 stocks declined, while 72 stocks hit the daily limit up and 17 stocks hit the daily limit down [1] Regional Performance - The Shanxi sector experienced a moderate increase of 0.41% on November 6, with a trading volume of 15.46 billion yuan, where 22 stocks rose, 14 stocks fell, and 5 stocks remained flat [1] - The overall positive market sentiment in the Shanxi sector is indicated by the majority of stocks rising, although the increase was modest, warranting attention to future trading volume changes [1] Individual Stock Performance - The top five performing stocks in Shanxi on November 6 included Shanxi Expressway, which led with a rise of 5.58%, followed by Huayang Co. with an increase of 4.28%, Huaxiang Co. up by 3.64%, Meijin Energy rising by 2.96%, and Northern Copper up by 2.24% [1] - Among the declining stocks, seven stocks fell by more than 1%, with Jinlihua Electric leading the decline at 3.71%, followed by Keda Automation down by 2.88%, and Jinbo Biological down by 2.54% [1]

Investment Rating - The report maintains an "Outperform" rating for Shanxi Jinbo Bio-Pharmaceutical, with a target price of RMB 297.04, indicating a potential upside of 16.3% from the current price of RMB 243.02 [2][15][16]. Core Insights - The core business growth has slowed, with revenue for 9M25 reaching RMB 1.296 billion, a year-on-year increase of 31.10%, while Q3 revenue was RMB 437 million, reflecting a slowdown to 13.36% year-on-year growth [3][12]. - The gross margin has declined, with a 9M25 gross margin of 90.8%, down 1.6 percentage points year-on-year, and a Q3 gross margin of 91.0%, down 2.6 percentage points year-on-year [3][12]. - Rising expenses are impacting profitability, with the sales expense ratio increasing to 22.3% in 9M25, up 5.0 percentage points year-on-year, and R&D expense ratio rising to 5.5%, up 1.1 percentage points year-on-year [3][12]. - The company is expanding production capacity significantly, with fixed assets under construction increasing by 1,074.29% from the beginning of the year, primarily for the production facility of injectable recombinant humanized collagen [4][13]. - The brand "Tongpin" achieved significant sales during the Double 11 shopping festival, generating approximately RMB 76 million in GMV, a 585% year-on-year increase [4][13]. Financial Summary - Revenue forecasts for 2025, 2026, and 2027 are RMB 1.863 billion, RMB 2.402 billion, and RMB 3.073 billion, with year-on-year growth rates of 29.1%, 28.9%, and 27.9% respectively [7][15]. - Net profit forecasts for the same period are RMB 820 million, RMB 1.067 billion, and RMB 1.362 billion, with growth rates of 12%, 30%, and 28% respectively [7][15]. - The report highlights a challenge in balancing cost control and growth quality, as sales expenses are growing faster than revenue [7][15].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company reported a revenue of 1.296 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 31.10%. The net profit attributable to shareholders was 568 million yuan, up 9.29% year-on-year [4][8] - The sales strategy for functional skincare products includes a focus on proprietary brands and targeted development of raw materials for major clients [8] - The company has successfully registered a new injectable-grade recombinant human collagen material, marking a significant breakthrough in high-end biomedical materials in China [8] Financial Performance Summary - For Q3 2025, the company achieved a revenue of 437 million yuan, with a year-on-year increase of 13.36% but a quarter-on-quarter decrease of 11.22%. The net profit for Q3 was 176 million yuan, down 16.24% year-on-year and 21.17% quarter-on-quarter [4] - The gross margin for the first three quarters of 2025 was 90.80%, a decrease of 1.57 percentage points year-on-year, while the net margin was 43.58%, down 9.02 percentage points year-on-year [8] - The company’s revenue projections for 2025-2027 are 2.041 billion yuan, 2.803 billion yuan, and 3.695 billion yuan, respectively, with year-on-year growth rates of 41.4%, 37.4%, and 31.8% [8][10] Valuation and Investment Recommendations - The current market valuation corresponds to a P/E ratio of 28.9 for 2025, 20.8 for 2026, and 15.5 for 2027 [8][10] - The company is positioned as a leader in the recombinant collagen market and is continuously expanding into new application areas [8]

Group 1: Industry Overview - The cosmetics retail sales in China grew by 3.9% year-on-year from January to September 2025, slightly underperforming the overall retail market by 0.6 percentage points, indicating a stable demand environment [4][14]. - Online platforms like Tmall and Douyin are experiencing a shift, with Tmall showing signs of recovery due to flash sales and member subsidies, while Douyin's growth has slightly slowed down [17][20]. - The demand for high-end and cost-effective products is increasing, while the mid-range segment is facing pressure due to a more conservative consumer environment [5][41]. Group 2: Competitive Landscape - The trend of domestic brands replacing foreign ones is slowing down, with leading foreign brands like L'Oréal and Estée Lauder showing signs of recovery in the Chinese market [23][24]. - The growth of domestic brands is becoming more differentiated, with some brands like Proya and Shiseido experiencing declines, while others like Youngor and Shanghai Jahwa continue to grow [23][24]. - The industry is witnessing an acceleration in the multi-brand matrix among leading companies, which is expected to increase market concentration [27][28]. Group 3: Key Companies - The report highlights several companies with strong growth potential, including Ruya Chen, Shumei Co., and Maogeping, which are expected to benefit from their brand strength and market positioning [3][54]. - Companies like Dekang Oral Care and Shanghai Jahwa are noted for their stable fundamentals and potential for marginal improvement, while others like Jinbo Biological and Huaxi Biological are anticipated to reach turning points [54]. - Ruya Chen's self-owned brand, Zhenjia, has shown significant growth, with a revenue increase of 345% year-on-year in Q3 2025, indicating strong brand development capabilities [60].

Group 1 - The medical beauty sector experienced a decline of 2.68% on November 4, with Jinbo Biological leading the drop [1] - The Shanghai Composite Index closed at 3960.19, down 0.41%, while the Shenzhen Component Index closed at 13175.22, down 1.71% [1] - Major stocks in the medical beauty sector showed varied performance, with *ST Meigu closing at 3.74 (+0.27%), Huaxi Biological at 52.05 (-2.01%), Aimeike at 151.92 (-3.46%), and Jinbo Biological at 243.02 (-4.84%) [1] Group 2 - The medical beauty sector saw a net outflow of 101 million yuan from institutional investors, while retail investors had a net inflow of 79.55 million yuan [1] - The trading volume and turnover for key stocks included *ST Meigu with 140,600 shares traded and a turnover of 53.3 million yuan, Huaxi Biological with 29,200 shares and 153 million yuan, Aimeike with 43,500 shares and 669 million yuan, and Jinbo Biological with 15,400 shares and 378 million yuan [1]

Core Viewpoint - Aimeike is at a critical transformation juncture, facing significant challenges after reporting its worst half-year and quarterly results, leading to a substantial decline in market confidence and valuation [2][3][12]. Financial Performance - In Q3 2025, Aimeike reported revenue of 565 million, a year-on-year decline of 21.27%, and a net profit of 304 million, down 34.61%. For the first nine months of 2025, revenue totaled 1.865 billion, a decrease of 21.49%, with net profit at 1.09 billion, down 31.05% [3][5]. - The company's market capitalization has plummeted to approximately 48.5 billion, a staggering drop of about 131.5 billion from its peak valuation of 180 billion in 2021, representing a cumulative decline of 73% [3][5]. Product Performance - Aimeike's core products, "Haitai" and "Ruhua Tianzi," have seen significant revenue declines. In the first half of 2025, "Haitai" generated 744 million, down 23.79%, while "Ruhua Tianzi" brought in 493 million, down 23.99% [6][8]. - Despite maintaining high gross margins above 90%, the revenue drop has raised concerns about the sustainability of Aimeike's growth model [8][10]. Competitive Landscape - The competitive advantage of Aimeike's core products is diminishing, with new entrants like Huaxi Biological's "Runzhi·Gege" entering the market, challenging the previously monopolistic position of "Haitai" [10][11]. - The emergence of alternative technologies, such as recombinant collagen, poses a threat to Aimeike's market share in the hyaluronic acid segment, further pressuring its performance [11]. Strategic Moves - To seek new growth avenues, Aimeike acquired 85% of South Korean company REGEN for 1.9 billion USD, aiming to enhance its product portfolio and international market access [12][13]. - This acquisition has led to a significant increase in goodwill from 278 million at the end of 2024 to 1.65 billion by the end of Q3 2025, marking a 493.44% increase [12]. Legal Challenges - Aimeike is embroiled in a legal dispute with REGEN's former distributor, which could impact the integration and future profitability of the acquisition, as the distributor is seeking 1.6 billion in damages [13].

Investment Rating - The investment rating for the company is "Accumulate" (maintained) [2] Core Views - The company reported a revenue of 1.296 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 31.1%, with a net profit attributable to shareholders of 568 million yuan, up 9.3% [8] - The company is focusing on expanding its product line, particularly with the launch of the new HiveCOL collagen product, which aims to lead the collagen anti-aging industry into a new era of "organizational regeneration" [8] - The company is expected to achieve net profits of 971 million yuan, 1.362 billion yuan, and 1.790 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding PE ratios of 29.1, 20.7, and 15.8 [8] Financial Performance Summary - Revenue projections for the company are as follows: 780 million yuan in 2023, 1.443 billion yuan in 2024, 2.049 billion yuan in 2025, 2.826 billion yuan in 2026, and 3.663 billion yuan in 2027, with growth rates of 100.0%, 84.9%, 42.0%, 37.9%, and 29.6% respectively [7] - The gross profit margin for Q3 2025 was reported at 91.0%, a decrease of 2.6 percentage points compared to the previous year [8] - The company’s R&D expenses are increasing due to collaborative research efforts, with the R&D expense ratio reaching 5.8% in Q3 2025, up 1.0 percentage points year-on-year [8] Market Strategy and Innovations - The company is adopting a dual-channel strategy of "online + offline" to enhance its market reach, particularly targeting younger demographics through increased online marketing efforts [8] - The company has successfully been included in the first batch of national-level industry intellectual property operation centers, which is expected to bolster its innovation capabilities [8] - The company is extending its collagen technology into innovative medical fields such as wound care dressings and orthopedic implant repair materials [8]

Market Overview - The medical beauty sector experienced a decline of 1.4% on November 3, with Ai Meike leading the drop [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Individual Stock Performance - *ST Meigu (000615) closed at 3.73, with an increase of 4.19% and a trading volume of 150,000 shares, totaling a transaction value of 5.5589 million yuan [1] - Jinbo Biological (920982) closed at 255.37, up 1.63%, with a trading volume of 15,700 shares and a transaction value of 403 million yuan [1] - Huaxi Biological (688363) closed at 53.12, down 1.61%, with a trading volume of 29,400 shares and a transaction value of 156 million yuan [1] - Ai Meike (300896) closed at 157.37, down 1.70%, with a trading volume of 33,400 shares and a transaction value of 5.271 billion yuan [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 2.7789 million yuan from main funds, while retail investors experienced a net outflow of 3.33256 million yuan [1] - Main funds for *ST Meigu showed a net inflow of 6.9892 million yuan, while retail investors had a net outflow of 652.99 thousand yuan [2] - Ai Meike had a net inflow of 1.4812 million yuan from main funds, but a net outflow of 1.89798 million yuan from retail investors [2] - Huaxi Biological experienced a net outflow of 5.6915 million yuan from main funds and a net outflow of 781.58 thousand yuan from retail investors [2]